Follow us on:

Linkedin Facebook

Aptamer Group to host webinar and Q&A session for investors

Aptamer Group

Aptamer Group plc (LON: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced that Dr Arron Tolley, Chief Executive Officer and Dr David Bunka, Chief Scientific Officer will be hosting a webinar on Thursday, 12 December 2024 at 6.00 pm (GMT).

The webinar will provide investors with a valuable opportunity to interact with Aptamer Group and gain insights into recent announcements.

There will be a Q&A session for investors after the presentation and questions can be submitted pre-event as part of the registration process.

You can register for the event by using the following link:

https://www.turnerpope.com/register/

We are delighted to announce that the webinar will be chaired by experienced news and corporate events presenter Katie Pilbeam (www.katiepilbeam.com) and hosted by the Company’s broker, Turner Pope Investments.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Latest Company News

    Aptamer Group

    Aptamer secures repeat contracts and new licensing deals

    Aptamer Group plc announces promising new data on its Optimer therapeutic delivery platform for liver fibrosis, showcasing broad therapeutic potential across various diseases.
    Aptamer Group

    Aptamer adapts Alzheimer’s test to ELISA and signs royalty deal

    Aptamer Group announces a breakthrough in Alzheimer's diagnostics with a new ELISA test utilising saliva samples, enhancing accessibility and rapid detection.
    Aptamer Group

    Aptamer licences Optimer binders for swine vaccines

    Aptamer Group plc has secured a significant global licensing deal with the University of Glasgow, advancing synthetic binders for vaccines in swine health.
    Aptamer Group

    Aptamer to present Optimer® liver targeting data at 2025 ASGCT

    Aptamer Group plc is set to unveil groundbreaking data on its Optimer® delivery vehicle for fibrotic liver disease at the 2025 ASGCT Annual Meeting.
    Aptamer Group

    Aptamer Group publishes new Corporate Presentation and Investor Factsheet

    Aptamer Group plc has released a new corporate presentation and investor factsheet, showcasing its strategic growth, operational progress, and financial performance in the life science industry.
    Aptamer Group

    Aptamer Group reports revenue growth and solid cash position in H1 2025

    Aptamer Group plc reports impressive interim results for H1 2025, highlighting revenue growth and strategic advancements in life sciences innovation.

      Latest interviews

      View all interviews 

      Company Presentations

      View all Company Presentations

      Brokers Talk

      View all Broker Talk

      FTSE 100 News

      Search

      Search

      Green News

      View all Sustainable sectors, Plcs and news  

      Q&A's

      View all Question and Answers

      Funds

      View all Funds, Market Insights and news

      UK Broker Ratings

      Hardman & Co

      Don't Miss Our News Alerts

      Subscribe Free

      Find us on:

      Linkedin Facebook

      Useful links

      Disclaimer

      You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

      © 2025 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.